Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Astrocytoma 8Glioblastoma 5Recurrence 3Oligodendroglioma 2Neuroectodermal Tumors, Primitive 2Neurocytoma 2Glioma 2Brain Neoplasms 2Optic Nerve Glioma 1Neurofibroma 1Neuroblastoma 1Neurilemmoma 1Meningioma 1Gliosarcoma 1Ganglioglioma 1Diffuse Intrinsic Pontine Glioma 1Craniopharyngioma 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 101Etoposide 60Carboplatin 55Vincristine 51Filgrastim 49Topotecan 44Temozolomide 44Melphalan 44Isotretinoin 44Doxorubicin 44Irinotecan 42Cisplatin 353-Iodobenzylguanidine 34Peripheral Blood Stem Cell Transplantation 31dinutuximab 30Granulocyte Colony-Stimulating Factor 30Radiotherapy 29sargramostim 28Granulocyte-Macrophage Colony-Stimulating Factor 25Busulfan 22Magnetic Resonance Spectroscopy 19aldesleukin 18Thiotepa 18fludarabine 17Interleukin-2 17humanized 3F8 anti-GD2 monoclonal antibody 16etoposide phosphate 16naxitamab 15Ifosfamide 15Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × antineoplaston AS 2-1 × CNS × Clear all
NCT00003513 2017-09-28

Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma

Burzynski Research Institute

Phase 2 Terminated
3 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡